GLP-1 receptor agonist drugs like Ozempic, Wegovy and Mounjaro have helped millions of Americans lose weight and better ...

Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the ...

Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.

Drug manufacturer Eli Lilly says their drug Zepbound is more effective than Wegovy for long-term weight loss. Results from a ...

Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...

A preliminary study on popular weight loss drugs finds participants shed more weight on Zepbound than on Novo Nordisk’s ...

It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...

Direct-to-consumer health and wellness company Ro will now offer access to lower-priced, single-dose vials of weight loss ...

Ro partners with Eli Lilly to offer Zepbound, an FDA-approved obesity treatment, at affordable cash-pay prices through an ...

NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...

Zepbound (tirzepatide) is a prescription drug that’s used for weight loss in certain adults. Zepbound comes as a liquid solution inside prefilled injection pens. You’ll inject the drug under ...

In March, the state’s Public Employee Insurance Agency (PEIA) decided it could no longer bear the crushing costs of Wegovy and Zepbound. (These obesity drugs are sometimes better known by the ...